Ең жақсы Химиотерапия дәрігерлері - ЖОҒ-139 дәрігерлер

Контент Bookimed редакциялық саясатына сәйкес келеді және оның сапасын тексерген

Фахад Мавлюд

Yusuf Acikgoz

  • 4.8 Керемет 5 пікірлер
  • 9 жылдар тәжірибе
  • Түркия, Анқара, Lokman Hekim University Ankara Hospital
  • Associate Professor Dr. Yusuf AÇIKGÖZ
    Specialization: Medical Oncology

    Education:

    • 2004-2011: İnönü University Faculty of Medicine
    • 2011-2016: Ankara Numune Training and Research Hospital, Internal Medicine
    • 2017-2022: Health Sciences University, Medical Oncology

    Professional Experience:

    • 2016-2017: Bingöl City Hospital, Internal Medicine
    • 2021-2022: Health Sciences University, Medical Oncology
    • 2022-2023: Kastamonu Education and Research Hospital, Medical Oncology
    • 2023-2024: Ohio State University, Medical Oncology
    • 2024-Present: Lokman Hekim University, Medical Oncology, Ankara Hospital

    Clinical Trials, Courses, Certifications:

    Clinical Trials:

    • 2017-2021: Phase III, CheckMate-649 Study (Assistant Investigator)
    • 2022-Present: Phase III, Fortitude-101 Study (Assistant Investigator)

    Courses:

    • 2018: Medicres Basic and Advanced Biostatistics Training Program (ongoing), Istanbul-Vienna
    • 2019: Immuno-Oncology Education Course, March 1-2, 2019, Vienna, Central European Cooperative Oncology Group (CECOG)
    • 2018: Good Clinical Practice Certification, April 7-8, 2018, Ankara, Health Sciences University
    • 2017: Basic Oncology Training Program, November 25-26, 2017, Adana, Clinical Oncology Society
    • 2016: Basic Ultrasonography Course (10 hours theoretical + 10 hours practical), September 24-25, 2016, Ankara, Turkish Emergency Medicine Association

    Certifications:

    • Ongoing: ECFMG Certification
    • 2024: CITI Responsible Conduct of Research (The Ohio State University)
    • 2024: CITI IACUC-Laboratory Animal Research (The Ohio State University)
    • 2024: CITI Human Subjects Protection (The Ohio State University)
    • 2024: CITI Good Clinical Practice (The Ohio State University)
    • 2023: Occupational English Test (OET)
    • 2019: International English Language Testing System (IELTS), Total Score: 6.5, May 26, 2019, Ankara, British Council
    • 2017: USMLE Step 2 CK Exam; Score: 244, February 7, 2017
    • 2016: USMLE Step 1 Exam; Score: 215, August 25, 2016

    Memberships:

    • American Society of Clinical Oncology (ASCO) - 2022
    • Turkish Society of Medical Oncology - 2020
  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Zhao Daobin

  • 3 Жақсы 1 пікірлер
  • 30 жылдар тәжірибе
  • Қытай, Бейжің, Lu Daopei Hematology Hospital
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Nail Paksoy

  • 4.5 Жақсы 2 пікірлер
  • 14 жылдар тәжірибе
  • аккредитациялар:
  • Түркия, Істанбұл, Medipol Bahçelievler Hospital

  • PROFESSIONAL EXPERIENCE

    2011-2012
    Erzurum Koprukoyu State Hospital
    Department: General Medicine

    2012-2017
    Istanbul University Cerrahpaşa Medical Faculty
    Department: Internal Medicine

    06/2017-10/2017
    Istanbul Gaziosmanpasa Taksim Training and Research Hospital
    Department: Internal Medicine

    10/2017-11/2018
    Istanbul University Istanbul Medical Faculty
    Department: Allergy and Immunology Fellowship

    2018/2022
    Istanbul University Oncology Institute
    Department: Medical Oncology Fellowship

    2022-2023
    Tekirdag City Hospital
    Department: Medical Oncology Specialist

    2023-present
    Istanbul Medipol University Medipol Bahcelievler Private Hospital
    Department: Medical Oncology Assoc. Prof.

     

    EDUCATION

    2005-2011
    Medical Education
    Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

    2012-2017
    Internal Medicine
    Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

    2017-2018
    Allergy-Immunology Fellowship
    Istanbul University Istanbul Medical Faculty
    Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

    2018-2022
    Medical Oncology Fellowship
    Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

    2022
    ESMO Board Certification in Medical Oncology
    10th September 2022 in Paris, France.

    2023
    Medical Oncology Assoc. Prof.
    Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

     

    INTERNATIONAL CLINICAL TRIALS:

    1. Astefania - ROCHE

    • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
    • Role: Subinvestigator

    2. PFİZER

    • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
    • Role: Subinvestigator

    3. RECITE - AMGEN

    • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
    • Role: Subinvestigator

    4. NAVIGATE - BAYER

    • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    • Role: Subinvestigator

    5. RUBY - Tesaro (PRA)

    • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
    • Role: Subinvestigator

    6. ENGOT-ov43/GOG-3036 - MSD

    • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
    • Role: Subinvestigator

    7. ASTRA ZENECA

    • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
    • Role: Subinvestigator

    8. ROSY-O - ASTRA ZENECA

    • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
    • Role: Subinvestigator
    •  

    INTERNATIONAL PUBLICATIONS

    I. Published journal articles indexed by SCI, SSCI, and AHCI

    Weekly Paclitaxel in Classic Kaposi Sarcoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
    • Journal: Medicine, 102(5)

    Carboplatin Desensitization in Ovarian Carcinoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
    • Journal: Medicine, 101(45), e31726

    High-Dose Chemotherapy for Ewing’s Sarcoma

    • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
    • Journal: Medicine, 101(49), e32213

    Multidrug Refractory TFE3(+) Renal Cell Carcinoma

    • Authors: Paksoy, Nail, et al.
    • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

    Crizotinib Efficacy in NSCLC with MET Alterations

    • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
    • Journal: Medicine, 101(50), e32368

    Clinicopathological Features in ALK Mutant NSCLC

    • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
    • Journal: Medicine, 101(34)

    PSMA-Based Tumor Burden in Prostate Cancer

    • Authors: HAS SIMSEK, Duygu, et al.
    • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

    Atezolizumab in Metastatic Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: European Urology Focus, 2021, 7.5: 1061-1066

    Pulmonary Sarcomatoid Carcinoma

    • Authors: FERHATOGLU, Ferhat, et al.
    • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

    Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

    Atezolizumab with Chemotherapy in Small Cell Lung Cancer

    • Authors: GÜRBÜZ, Mustafa, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

    FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

    • Authors: AY, Seval, et al.
    • Journal: Journal of Chemotherapy, 2022, 1-7

    Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

    • Authors: CIL, Ibrahim, et al.
    • Journal: Tumori Journal, 2022, 108.1: 19-25

    Real-Life Efficacy of Osimertinib in Advanced NSCLC

    • Authors: HIZAL, Mutlu, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

    ALK-Positive Cells Percentage and Alectinib Efficacy

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
    • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

    Real-World Data on Alectinib in ALK-Positive NSCLC

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
    • Journal: Future Oncology, 18(23), 2573-2582

    Prognostic Factors in Metastatic RCC with T790M Mutation

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

    • Authors: DEMIR, Semra, et al.
    • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

    Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

    • Authors: ÖZDEMIR, Seçil Kepil, et al.
    • Journal: Allergy, 2019, 74.6: 1187-1190

    Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

    • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
    • Journal: The Oncologist, oyad257

    Subsequent Treatments in Hormone-Positive Breast Cancer Progression

    • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
    • Journal: BMC cancer, 23(1), 192

    Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
    • Journal: Scientific Reports, 13(1), 8779

    Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
    • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

    Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

    • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
    • Journal: European Journal of Breast Health, 19(2), 128

    Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

    • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
    • Journal: Future Oncology, 19(10), 727-736

    Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

    • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
    • Journal: [Not specified]

    Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

    • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
    • Journal: Medicine, 102(39), e35383

    Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

    • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
    • Journal: Medicine, 102(41), e35245

    Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

    Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

    Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

    Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

    Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

    Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

    Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

    Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

    Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

    Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

    Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

    Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

    Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

     

    Thesis:

    Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

    International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

    Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

    • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

    Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

    • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

    Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

    • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

    Efficacy of temozolomide in pretreated patients with metastatic sarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

    • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

    • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

    Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

    • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

    Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

    • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

    Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

    • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

     

     

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Itir Sirinoglu Temiz

  • 5 Керемет 7 пікірлер
  • 35 жылдар тәжірибе
  • Түркия, Істанбұл, Liv Hospital Vadistanbul
  • Dr. Itir Sirinoglu Temiz is a Professor of Hematology. She specializes in lymphoma, acute and chronic leukemias, multiple myeloma, thrombocytopenias, thrombosis, anemia, and bone marrow failure. She graduated with honors from Istanbul University Cerrahpaşa Faculty of Medicine. She completed her hematology training at Dr. Abdurrahman Yurtarslan Oncology Education and Research Hospital.

    Dr. Sirinoglu Temiz has held key academic and administrative positions. She served as Head of Internal Medicine at IAU Faculty of Medicine. She was also Education and Administrative Manager at SBÜ Bakırköy Dr. Sadi Konuk EAH Hematology Clinic. She has broad experience in adult hematology, stem cell transplantation, and therapeutic apheresis. She currently practices at Liv Hospital.

  • Толығырақ оқу
Химиотерапия
3 000 $ - 3 500 $
Ақпарат

Sherko Kuemmel

  • Жаңа
  • 28 жылдар тәжірибе
  • Кипр, Кипр Республикасы, German Medical Institute (GMI)
  •  Posts and Affiliations

    Clinical Director – Multidisciplinary Breast Unit Kliniken Essen-Mitte, Germany

    Lead Breast Cancer Research Program, Kliniken Essen-Mitte

    Executive Board Member of the AGO (Arbeitsgemeinschaft Gynäkologische Onkologie)

     Additional Roles

    ESMO Faculty – Breast Cancer

    Member of AWO Gyn – Commission for plastic and reconstructive surgery

    Speaker of the AGIMed – Commission for Integrative Medicine of the AGO

    Member of the Organ Commission Mamma of the AGO

    Scientific Director of the WSG study group

    Global PI, Head of clinical investigations and trials 27

    IDMC´s, Steering Boards national and international

    Scientific committee of international and national symposia in breast cancer and surgical oncology

     Organization Memberships

    Memberships: European Society of Medical Oncology, American Society of Clinical Oncology,

    European Academy of Senology, German Cancer Society, German Society of Gynecology and

    Obstetrics, Working Group for Gynecological Oncology, German Society of Senology,

     Publications

    Peer reviewed Publications: 322

    First/Senior Author: 38

    h-Index/i10-Index 66/232

    Congress Abstracts/Proceedings: 443

    Books/Book Chapter: 59

    Invited oral Presentations/Lectures: 1032

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Tarik Salman

  • Жаңа
  • 31 жылдар тәжірибе
  • Түркия, Ізмір, Medicalpoint International Hospital
  • Diseases

    • Lung Cancer
    • Skin Cancers
    • Gastrointestinal Cancers
    • Genitourinary Cancers
    • Gynecological Cancers
    • Colon Cancer
    • Breast Cancer
    • Rare Cancers

    Treatment Methods

    • Individual Treatments (Comprehensive Genomic Profiling)
    • Targeted Therapies
    • Immunotherapy
    • Cancer Vaccines
    • Chemotherapy
    • Clinical Research/Experimental Medical Research

    Experience

    • 2017- 2024: Katip Çelebi University Faculty of Medicine Atatürk Education and Research Hospital Medical Oncology Clinic Associate Professor / Lecturer
    • 2022 December – 2023 March: Academic visitor Moffitt Cancer Center Cutaenous Oncology Clinic Tampa, Florida USA
    • 2013- 2017: Katip Çelebi University Faculty of Medicine Atatürk Training and Research Hospital – Medical Oncology Clinic Specialist Physician
    • 2012-2013: Izmir Education and Research Hospital, Medical Oncology Specialist Physician
    • 2012-2012: Mersin State Hospital, Medical Oncology Specialist Physician
    • 2010-2012: Dokuz Eylül University Faculty of Medicine, Department of Medical Oncology, Sub-branch Research Assistant
    • June-August 2008, December 2008 – February 2009: Memorial Sloan Kettering Cancer Center Observership programme
    • 2007-2009: Kartal Education and Research Hospital, Medical Oncology Sub-branch Research Assistant
    • 2006-2007: Siirt State Hospital, Internal Medicine, Specialist Physician
    • 2005-2006: Çukurova University Faculty of Medicine, Medical Oncology Sub-branch Research Assistant
    • 2004-2005: SSK Siirt Hospital, Internal Medicine Specialist Physician
    • 2003-2004: SSK Mardin Hospital, Internal Medicine Specialist Physician
    • 1998-2003: SSK Izmir Training and Research Hospital, 3rd Internal Medicine Clinic, Research Assistant
    • 1998-1998: SSK Izmir Training and Research Hospital Infectious Diseases Research Assistant
    • 1997-1998: Izmir Ataturk Training and Research Hospital, Anesthesiology and Reanimation Clinic, Research Assistant
    • 1995-1997: Şırnak Cizre Central Health Center
    • 1994-1995: Şırnak İdil Oyalı Village Health Center

    Professional Memberships

    • Turkish Society of Medical Oncology 2008 
    • (2018-2021 Term Board Member)
    • Izmir Oncology Group, Board Member (2014 -…)
    • Geriatric Oncology Association, Board Member (2015-…)
    • Mediterranean Oncology Association Board Member (2020 -…)
    • Turkish Biochemistry Association, Member, 2016
    • European Society of Medical Oncology, Member, 2012
    • American Society of Clinical Oncology, Member, 2008
  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Kodchanut Litleaungdej Md

  • 4.5 Жақсы 2 пікірлер
  • 11 жылдар тәжірибе
  • Таиланд, Баңкөк, Intrarat Hospital
  • Kodchanut Litleaungdej, M.D.

    EDUCATION 
     
    • High school: Benjamarachalai school under the royal patronage 2008
    • Graduated MD from faculty of Medicine, Naresuan university hospital 2014 (GPA  3.41 Second Honor)
    • Graduated Thai Board of hematology on July,2020 from haematology fellowship at Haematology unit, Department of Internal medicine, faculty of medicine, Thammasat University.
    WORK EXPERIENCES & PRACTICES
     
    • Internist at Pranangklao hospital 2014
    • Internist at Bangbuatong hospital 2015-2017
    • Resident Hematology at Thammasat university hospital since July,2017
    • Working as Haematologist (Pioneer) at Huahin hospital since 2020
    OTHER EXPERIENCES
    2015-2017 Instructor nursing student at Sai noi hospital and Bangbuatong hospital 
    2015 Member of Pharmacy and Therapeutics Committee at Bangbuatong hospital 
    2015 Emergency Medicine, organized by Phramongkutklao hospital
    2016 Update in internal medicine, organized by Siriraj hospital
    2016 Ambulatory medicine, organized by Chulalongkorn-Ramathibodi-Siriraj 
    hospita
    2016 5th ECG workshop, organized by Chulalongkorn hospital
    ACADEMIC ACHIEVEMENTS
     Co-author in: Development and validation of a cancer-associated venous thromboembolism 
    clinical risk prediction (CAT-CR) model >> waiting for publication
  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Oscar Arrieta

  • Жаңа
  • 32 жылдар тәжірибе
  • Мексика, Мехико, DR. IRERI ASTEINZA Clinic
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Osman Kostek

  • 5 Керемет 3 пікірлер
  • 21 жылдар тәжірибе
  • Түркия, Істанбұл, Medipol Acibadem District Hospital
  • Education

    • (2004 – 2011), Faculty of Medicine/ Inonu University/ Malatya, Turkiye
    • (2011 – 2015), Department of Radiology/ Bagcilar Training and Research Hospital/ Istanbul, Turkiye

    Career

    • (2016 – 2020), Diagnostic and Interventional Radiologist/ Mus State Hospital/ Mus,Turkiye
    • (2020 – 2022), Assistant Professor of Diagnostic and Interventional Radiology/ Sakarya University Training and Research Hospital/ Sakarya, Turkiye
    • (2023 – 2024), Associate Professor of Diagnostic and Interventional Radiology /Sakarya University Training and Research Hospital/ Sakarya, Turkiye
    • (2024 - Present), Associate Professor of Diagnostic and Interventional Radiology /Medipol University Hospital/ Istanbul, Turkiye
  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Nir Peled

  • 4 Жақсы 1 пікірлер
  • аккредитациялар:
  • Израиль, Герцлія, Herzliya Medical Center
  • Prof. Peled is a leading specialist in lung cancer immunotherapy, with expertise in Internal Medicine, Pulmonology and Medical Oncology. He has received the ASCO Merit Award, and is the head of the Thoracic Cancer Unit at Davidoff Cancer Center and Head of the Research and Detection Unit for Thoracic malignancies at Sheba Medical Center. He is a member of the Thoracic Oncology Assembly of the European Respiratory Society and Chair of the Early Detection and Prevention Committee of the International Association for the Study of Lung Cancer.

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Tamar Jablonski-Perec

  • 4.4 Жақсы 12 пікірлер
  • Израиль, Іерусалім, Hadassah Medical Center
  • Dr. Tamar Jablonski-Perec is an oncologist at Hadassah Medical Center in Jerusalem. She holds a Doctor of Medical Sciences from the Hebrew University and has experience from the renowned Sloan-Kettering Cancer Center in New York. She is the Head of Institute of Oncology, Head of Breast Cancer Treatment Center, and Professor of the Department of Oncology at the Hebrew University. She is a member of several international cancer communities and was awarded a scholarship from the Hadassah Medical School.

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Ella Tepper

  • 4.4 Жақсы 13 пікірлер
  • Израиль, Тель-Авів, Assuta Medical Center
  • Chief Physician of the Oncology Center, Oncologist

Ақпарат

Moshe Inbar

  • 4.4 Жақсы 13 пікірлер
  • аккредитациялар:
  • Израиль, Тель-Авів, Assuta Medical Center
  • Prof. Moshe Inbar is an Israeli oncologist and the Head of Department of Oncology at Sourasky (Ichilov) Medical Center, specializing in breast cancer, cancer of the uterus and ovaries, urogenital cancer in female and male, and gastro-intestinal cancer. He is a Clinical Associate Professor in Tel Aviv University, holds numerous awards and is a member of various research organizations.

  • Толығырақ оқу
Ақпарат

Ofer Spielberg

  • 4.4 Жақсы 13 пікірлер
  • Израиль, Тель-Авів, Assuta Medical Center
  • Oncohematologist

Ақпарат

Irina Zhevelyuk

  • 4.4 Жақсы 13 пікірлер
  • Израиль, Тель-Авів, Assuta Medical Center
  • Oncologist, Radiologist

Ақпарат

Miriam Ben-Harush

  • 5 Керемет 2 пікірлер
  • аккредитациялар:
  • Израиль, Хайфа, Rambam Medical Center
  • Children's Oncologist

    Head of the Department of Pediatric Hematology and Oncology.

Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Karen Drumea

  • 5 Керемет 2 пікірлер
  • Израиль, Хайфа, Rambam Medical Center
  • Radiotherapy specialist, Oncologist

Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Francesc Bosch

  • 4.4 Жақсы 6 пікірлер
  • 125 жылдар тәжірибе
  • Испания, Барселона, Hospital Quiron Barcelona
  • Dr. Francesc Bosch is an expert in Chronic Lymphocytic Leukemia (CLL) and lymphomas. He leads research in the molecular causes and new treatments for CLL and other lymphoproliferative disorders.

    He has published over 100 articles in leading journals, including The New England Journal of Medicine and Nature Medicine. Dr. Bosch oversees more than 80 clinical studies, from phase 1 to phase 3, and plays a key role in developing new drugs.

    He is the Head of Hematology at Vall d’Hebron University Hospital and IOB Institute of Oncology. He also serves as president of GELLC and is a professor of hematology. His work has improved diagnosis and treatment for blood diseases.

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Ana Oaknin

  • 4.4 Жақсы 6 пікірлер
  • 25 жылдар тәжірибе
  • аккредитациялар:
  • Испания, Барселона, Hospital Quiron Barcelona
  • Dr. Ana Oaknin is a Medical Oncologist with expertise in angiogenesis, DNA repair, and immunology. She focuses on gynecological cancers. Dr. Oaknin earned her medical degree and MD in Medical Oncology from Complutense University of Madrid. She also holds a PhD from Universidad Autonoma de Barcelona.

    Dr. Oaknin is Co-Chair of the GEICO Group. She is a faculty member for the Gyn-Track in the European Society of Medical Oncology. She represents Spain in the GOG and GCIG committees. Dr. Oaknin is an active member of ASCO, ESMO, and SEOM. She has published over 100 scientific articles and presentations. She also leads several clinical trials in ovarian, cervical, and endometrial cancer.

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Aleix Prat

  • 4.4 Жақсы 6 пікірлер
  • 22 жылдар тәжірибе
  • Испания, Барселона, Hospital Quiron Barcelona
  • Dr. Aleix Prat is a clinical scientist with expertise in breast cancer research, gene expression, and clinical trials. He earned his MD from the University of Barcelona. He completed his oncology fellowship at Vall d’Hebron Institute of Oncology. Dr. Prat leads the Translational Genomics and Targeted Therapeutics in Solid Tumors Group at IDIBAPS. He is also President of SOLTI and serves on the Executive Committee of The Breast International Group.

    Dr. Prat has published over 160 scientific papers. His work has received 13,479 citations, and he has an H-Index of 51. He is a Tenure-Track Professor at the University of Barcelona. He also directs the Breast Pathology–Senology Master’s degree. His roles highlight his strong academic and clinical contributions to oncology.

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Дәрігер мен клиниканы дұрыс қалай таңдау керек: сарапшылардың ұсыныстары

Дәрігер немесе клиника таңдағанда осы негізгі сәттерді есте сақтаңыз:
Біліктілікті тексеріңіз
ISAPS, JCI және т.б. сияқты ұйымдардан сертификаттардың болуына көз жеткізіңіз.
Процедуралардың табыстылығы туралы біліңіз
Сізге қажет саладағы үлкен тәжірибесі бар дәрігерлерді таңдаңыз.
Науқастардың пікірлерін оқыңыз
Олардың тәжірибесі туралы тікелей білу үшін Bookimed сайтындағы нақты науқастардың пікірлерімен танысыңыз.
Тиімді коммуникация мүмкіндігіне көз жеткізіңіз
Сіздің барушы максималды жайлы өтуі үшін аудармашы қызметтерін ұсынатын клиникаларды таңдаңыз.
Қолжетімді қызметтер туралы сұраңыз
Клиника тұрғын үй және трансфер ұсына ма, сондай-ақ бағаларды біліңіз.
Шетелде клиника таңдау қиын болуы мүмкін. Bookimed командасы 800 мыңнан астам науқасқа көмектесті және Сіздің алаңдаушылықтарыңызды түсінеді. Біз сенімді дәрігерлерді, баға мен сапаның ең жақсы арақатынасы бар нұсқаларды және тіпті күрделі жағдайлар үшін шешімдерді қалай табуды білеміз. Біз осы жолдың әрбір қадамында Сізді қолдауға дайынбыз.
Ян Мациевский
Дәрігер-координаторлар тобының басшысы